C Partners Holding’s Myriad Genetics MYGN Stock Holding History

C Partners Holding’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,724	Closed	-$125K	–	158
2018 Q3	$125K	Sell	2,724 -4,827	-64%	-$215K	0.04%	107
2018 Q2	$282K	Buy	7,551 +1,511	+25%	+$51K	0.11%	23
2018 Q1	$178K	Sell	6,040 -1,615	-21%	-$54.6K	0.07%	250
2017 Q4	$263K	Buy	+7,655	New	+$258K	0.11%	183

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

C Partners Holding's MYGN Position: Q4 2018 in Review

C Partners Holding sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 2,724 shares — an estimated $125K sold.

C Partners Holding first reported a position in MYGN in Q4 2017 and held it in 4 quarters. The position peaked at $282K in Q2 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

C Partners Holding reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
C Partners Holding sold 2,724 Myriad Genetics shares in Q4 2018, an estimated $125K.
C Partners Holding first reported a position in Myriad Genetics in Q4 2017 and held it in 4 quarters.
C Partners Holding's Myriad Genetics position peaked at $282K in Q2 2018.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on C Partners Holding's 13F filing for Q4 2018, filed 7 Feb 2019.